All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

The Pharmacist’s Guide to Patient Identification, Testing, and Antiviral Use.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


Cystic Fibrosis Module #3: Management of Acute Pulmonary Exacerbations: Pseudomonas and Beyond

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

View the other Modules in this CSPE Core Curriculum Series:
Cystic Fibrosis Module #1: Cystic Fibrosis: An Overview for Pharmacists 

Cystic Fibrosis Module #2: Chronic Medications: Changing the Course of Cystic Fibrosis 

Cystic Fibrosis Module #4: Adherence, Access, Education: Current Challenges and Overcoming Barriers in CF Medications 


This activity is available for free to members of NASP. Visit the top section of for details.


A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities

Activity Description

Cystic Fibrosis (CF) is an inherited chronic disease caused by a gene defect. It is estimated to occur in about 1 in every 3500 children born in the United States. This complex disease can affect the lungs, the digestive system, and other organs resulting in a high morbidity and mortality. CF can also affect the pharmacokinetics of many drugs and this needs to be considered when prescribing medications to CF patients. CF has no known cure, but treatments are available to help modify the disease process. The modules of this program will provide information on the disease and treatments for the CF patient as well as address other important challenges and considerations in CF patients. Module 3 addresses the management of infections in CF patients and the use of antibiotics in CF patients. It will review the pharmacokinetic and pharmacodynamic considerations to in these patients.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:

  • Identify a dose and frequency of administration to optimize benefit and minimize toxicity of anti-pseudomonal antibiotics
  • List two pharmacokinetic (PK)/pharmacodynamic (PD) advantages of continuous infusion (CI) versus intermittent antibiotics
  • Describe an antibiotic dosing regimen to treat non-pseudomonal CF pathogens


Jeffery T. Zobell, PharmD, BCPPS
Advanced Clinical Pharmacist
Intermountain Primary Children's Hospital
Intermountain Cystic Fibrosis Pediatric Center
Salt Lake City, Utah


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Jeffery Zobell does not have any relevant commercial and/or financial relationships to disclose.

CE Accreditation

Release Date: May 15, 2020
Expiration Date: May 15, 2023


This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-214-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


No external support has been received for this activity.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.